Crossmark

DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma

Crossref DOI link: https://doi.org/10.1007/s00432-018-2771-9

Published Online: 2018-10-16

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Xin-Yu

Liang, Jin-Hua

Wang, Li

Zhu, Hua-Yuan

Wu, Wei

Cao, Lei

Fan, Lei

Li, Jian-Yong

Xu, Wei https://orcid.org/0000-0003-4208-7477
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81370657)

National Natural Science Foundation of China (81770166)

National Natural Science Foundation of China (81470328)

National Natural Science Foundation of China (81720108002)

National Natural Science Foundation of China (81600130)
License Information

Text and Data Mining valid from 2018-10-16
More Information

Article History

Received: 18 March 2018

Accepted: 11 October 2018

First Online: 16 October 2018

Compliance with ethical standards

:

: The authors declare no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

: Informed coansent was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below